Physician profile
Ronald Mark Levy
NPI 1558350975
$7,999.82
in general payments reported to CMS, 2019-2025
43 companies · $2,331 in 2025
The $2,331 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $447 · 2021: $935 · 2022: $1,028 · 2023: $920 · 2024: $1,345 · 2025: $2,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,319 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,319.49 |
| Education | $276.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,855.87 | 2019-2025 | |
| Janssen Biotech, INC. | $1,122.99 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $670.25 | 2019-2025 | Xifaxan |
| Celgene Corporation | $431.15 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $393.92 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $319.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $288.40 | 2019-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $246.38 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $232.14 | 2021-2025 | Eohilia, Entyvio, Gattex |
| Braintree Laboratories, INC. | $215.86 | 2019-2024 | Suflave, Sutab |
| Pfizer INC. | $212.22 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $197.31 | 2019-2025 | Ocaliva |
| Allergan, INC. | $195.74 | 2019-2020 | |
| Ardelyx, INC. | $165.23 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $157.33 | 2025 | Wegovy |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.